These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9247410)

  • 1. Carnitine for valproic acid-induced hyperammonemia.
    Raby WN
    Am J Psychiatry; 1997 Aug; 154(8):1168-9. PubMed ID: 9247410
    [No Abstract]   [Full Text] [Related]  

  • 2. Valproate-associated hyperammonemia and DL-carnitine supplement.
    Komatsu M; Kodama S; Yokoyama S; Konishi H; Tanaka K; Momota K; Wada H; Matsuo T
    Kobe J Med Sci; 1987 Jun; 33(3):81-7. PubMed ID: 2959815
    [No Abstract]   [Full Text] [Related]  

  • 3. Carnitine deficiency and hyperammonemia associated with valproic acid therapy.
    Ohtani Y; Endo F; Matsuda I
    J Pediatr; 1982 Nov; 101(5):782-5. PubMed ID: 6813444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
    Hamed SA; Abdella MM
    Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperammonemia due to valproic acid in the psychiatric setting.
    Carr RB; Shrewsbury K
    Am J Psychiatry; 2007 Jul; 164(7):1020-7. PubMed ID: 17606652
    [No Abstract]   [Full Text] [Related]  

  • 6. Valproate-induced hyperammonemia.
    Batshaw ML; Brusilow SW
    Ann Neurol; 1982 Mar; 11(3):319-21. PubMed ID: 6807193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy.
    Inoue K; Suzuki E; Takahashi T; Yamamoto Y; Yazawa R; Takahashi Y; Imai K; Miyakawa K; Inoue Y; Tsuji D; Hayashi H; Itoh K
    Epilepsy Res; 2014 Aug; 108(6):1046-51. PubMed ID: 24888247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asymptomatic hyperammonemia in children treated with valproic acid.
    Altunbaşak S; Baytok V; Tasouji M; Hergüner O; Burgut R; Kayrin L
    J Child Neurol; 1997 Oct; 12(7):461-3. PubMed ID: 9373804
    [No Abstract]   [Full Text] [Related]  

  • 9. Ammonia induced encephalopathy from valproic acid in a bipolar patient: case report.
    Elgudin L; Hall Y; Schubert D
    Int J Psychiatry Med; 2003; 33(1):91-6. PubMed ID: 12906346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carnitine supplementation for valproate-related hyperammonemia to maintain therapeutic valproate level.
    Sonik P; Hilty DM; Rossaro L; Bourgeois JA
    J Clin Psychopharmacol; 2011 Oct; 31(5):680-2. PubMed ID: 21881462
    [No Abstract]   [Full Text] [Related]  

  • 11. [Cerebral edema with hyperammonemia in valpromide poisoning. Manifestation in an adult, of a partial deficit in type I carbamylphosphate synthetase].
    Bourrier P; Varache N; Alquier P; Rabier D; Kamoun P; Lorre G; Alhayek G
    Presse Med; 1988 Nov; 17(39):2063-6. PubMed ID: 2974563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients].
    Navarro-Quesada FJ; Lluch-Fernández MD; Vaquero-Abellán M; Marchante-Serrano C; Jiménez C
    Rev Neurol; 1997 Jul; 25(143):1037-44. PubMed ID: 9280630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carnitine and/or Acetylcarnitine Deficiency as a Cause of Higher Levels of Ammonia.
    Maldonado C; Guevara N; Queijo C; González R; Fagiolino P; Vázquez M
    Biomed Res Int; 2016; 2016():2920108. PubMed ID: 26998483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.
    Verbiest HB; Straver JS; Colombo JP; van der Vijver JC; van Woerkom TC
    Acta Neurol Scand; 1992 Sep; 86(3):275-9. PubMed ID: 1414247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The problems of valproate therapy in severely handicapped children--valproate induced hyperammonemia and hypocarnitinemia].
    Matsui K; Iwamoto H; Ohtsuki N; Kobayashi T; Miyake S; Yamada M
    No To Hattatsu; 1991 Jan; 23(1):32-8. PubMed ID: 1825272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sudden valproate-induced hyperammonemia managed with L-carnitine in a medically healthy bipolar patient: Essential review of the literature and case report.
    Cattaneo CI; Ressico F; Valsesia R; D'Innella P; Ballabio M; Fornaro M
    Medicine (Baltimore); 2017 Sep; 96(39):e8117. PubMed ID: 28953637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [L-carnitine in valproic acid-induced hyperammonemia].
    Martín-del Rincón JP; Llompart-Pou JA; Ferreruela M; Velasco J
    Med Intensiva; 2014 Mar; 38(2):124-5. PubMed ID: 23017629
    [No Abstract]   [Full Text] [Related]  

  • 18. Hyperammonemia associated with valproic acid concentrations.
    Vázquez M; Fagiolino P; Maldonado C; Olmos I; Ibarra M; Alvariza S; Guevara N; Magallanes L; Olano I
    Biomed Res Int; 2014; 2014():217269. PubMed ID: 24868521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-Carnitine supplementation to reverse hyperammonemia in a patient undergoing chronic valproic acid treatment: A case report.
    Maldonado C; Guevara N; Silveira A; Fagiolino P; Vázquez M
    J Int Med Res; 2017 Jun; 45(3):1268-1272. PubMed ID: 28425821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valproate-induced hyperammonemia in the psychiatric setting: 2 cases.
    Panikkar GP; Gilman SM
    J Clin Psychiatry; 1999 Aug; 60(8):557-9. PubMed ID: 10485644
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.